Compare Costco Wholesale Corporation (COST) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Medpace Holdings Inc — how do they compare? Costco Wholesale Corporation trades at $946.4 (market cap $420.05B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Costco Wholesale Corporation is far larger — about 25× Medpace Holdings Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Medpace Holdings Inc for 14 Days on average.
| COST | MEDP | |
|---|---|---|
Market Cap | $420.05B | $16.82B |
Volume | 2,087,565 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $630.19 |
52-Week Low | $849.63 | $393.42 |
Typical Hold Time | 133 Days | 14 Days |
Enterprise Value | $407.33B | $16.44B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $946.92, up 0.5% today, near its pivot point of $947. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, revenue grew to $275.24B in 2025 with a net income margin of 3.04%, while the P/E ratio of 45.66 reflects a premium valuation. Recent news highlights strong March sales growth of 11.3% year-over-year and a membership fee increase, signaling pricing power.
The outlook remains positive with analyst consensus strongly favoring Buy (66.1%) and a price target of $1,100, implying ~16% upside. Key risks include high valuation sensitivity and competitive pressures. Earnings growth and membership renewal rates are critical catalysts for sustained appreciation, but any miss could trigger a pullback.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
